The Medical Letter on Drugs and Therapeutics
CYP3A and Drug Interactions
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Serious adverse interactions between drugs continue to be reported.1 Many of these are due to inhibition or induction of cytochrome P450 (CYP) enzymes, particularly CYP3A4. CYP3A is thought to be involved in the metabolism of more than 50 percent of currently prescribed drugs.2 CYP3A4, which is more abundantly expressed than CYP3A5, accounts for most CYP3A activity in vivo.

TESTING —The FDA has established standards for in vitro testing of new drugs to predict CYP-related interactions.3 Liver microsomes and CYP3A-overexpressing cells can be used to assess metabolism by and inhibition or induction of CYP3A. In addition to in vitro testing, targeted clinical drug interaction studies in healthy volunteers may be required.

CYP3A — The clinical consequences of altering any pathway of drug elimination depend ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: CYP3A and Drug Interactions
Article code: 1212b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian